Investor Relations

Sensus Healthcare, Inc. (NASDAQ: SRTS; SRTSW) is a medical device company that is committed to enabling non-invasive and cost-effective treatment of non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy x-ray radiation technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development activities. Sensus has successfully incorporated the SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, the SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients.

LHA Investor Relations
Kim Sutton Golodetz
212 838 3777
kgolodetz@lhai.com

NASDAQSRTS
Recent News
Sep 17, 2018

Sensus Healthcare, Inc. (Nasdaq: SRTS) announced today that it completed a public offering of 2,205,882 shares of its common stock, par value $0.01 per share, at a public offering price of $6.80...

Sep 13, 2018

Sensus Healthcare, Inc. (Nasdaq: SRTS) announced today that it has priced an underwritten public offering of 2,205,882 shares of its common stock, par value $0.01 per share, at a public offering...

Read More

Recent Events
SUBSCRIBE
Subscribe for Investor updates
* Required Fields
Products in Development - Evofem